For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Collaboration revenue - related party | - | 0 | 0 | 0 |
| Research and development | 32,003,000 | 28,632,000 | 31,164,000 | 40,156,000 |
| Impairment of long-lived asset | - | 0 | 0 | 2,382,000 |
| General and administrative | 14,089,000 | 13,772,000 | 13,737,000 | 14,281,000 |
| Total operating expenses | 46,092,000 | 42,404,000 | 44,901,000 | 56,819,000 |
| Loss from operations | -46,092,000 | -42,404,000 | -44,901,000 | -56,819,000 |
| Interest and other income, net | 3,573,000 | 3,660,000 | 3,926,000 | 6,187,000 |
| Interest expense | 300,000 | 313,000 | 344,000 | 268,000 |
| Other income (expenses), net | 212,000 | 247,000 | -81,000 | -43,000 |
| Total other income (expenses), net | 3,485,000 | 3,594,000 | 3,501,000 | 5,876,000 |
| Loss before income taxes | - | -38,810,000* | - | - |
| Tax benefit at federal statutory rate | - | -10,021,500* | - | - |
| Research tax credits | - | 445,750* | - | - |
| Change in valuation allowance | - | 8,853,500* | - | - |
| Stock-based compensation | - | 1,570,000* | - | - |
| Other | - | 43,750* | - | - |
| Other adjustments | - | 0* | - | - |
| Income tax expense | - | 0* | - | - |
| Net loss | -42,607,000 | -38,810,000 | -41,400,000 | -50,943,000 |
| Net unrealized gain (loss) on available-for-sale investments | -452,000 | 34,000 | 280,000 | -88,000 |
| Net comprehensive loss | -43,059,000 | -38,776,000 | -41,120,000 | -51,031,000 |
| Basic EPS | -0.18 | -0.171 | -0.19 | -0.23 |
| Diluted EPS | -0.18 | -0.171 | -0.19 | -0.23 |
| Basic Average Shares | 240,290,782 | 226,163,829 | 222,038,680 | 218,929,548 |
| Diluted Average Shares | 240,290,782 | 226,163,829 | 222,038,680 | 218,929,548 |
Allogene Therapeutics, Inc. (ALLO)
Allogene Therapeutics, Inc. (ALLO)